Vertex Pharmaceuticals Incorporated (VRTX) Is a Trending Stock: Facts to Know Before Betting on It

Vertex (VRTX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Zacks Investment Research • 5 hours ago

Here's Why Vertex Was Willing to Pay a Premium of More Than 100% for Crinetics Pharmaceuticals

Atumelnant is a promising treatment for congenital adrenal hyperplasia that could be a key part of Vertex's future. Management says it was "floored" by its results in clinical trials.

The Motley Fool • Jul 14, 2026

Vertex Pharmaceuticals (VRTX) Declines More Than Market: Some Information for Investors

Vertex Pharmaceuticals (VRTX) reached $480.25 at the closing of the latest trading day, reflecting a -1.06% change compared to its last close.

Zacks Investment Research • Jul 13, 2026

Does Vertex's Acquisition of Crinetics Pharmaceuticals Make the Stock a No-Brainer Buy?

Vertex is buying Crinetics Pharmaceuticals for $10 billion. The acquisition could add up to $5 billion in revenue.

The Motley Fool • Jul 13, 2026

Vertex Pharmaceuticals Bets $10 Billion on Crinetics to Build Endocrinology Powerhouse

Vertex Pharmaceuticals NASDAQ: VRTX said it has entered into a definitive agreement to acquire Crinetics Pharmaceuticals for $85 per share in cash, a transaction Vertex executives described as a strategic expansion into specialty endocrinology.

MarketBeat • Jul 11, 2026

Vertex Pharmaceuticals Just Made a $10 Billion Move. Is the Stock a Buy?

Vertex Pharmaceuticals is the global leader in cystic fibrosis treatments, and this has translated into billion-dollar earnings. The biotech has taken key steps in recent years to expand into other treatment areas, and efforts have been bearing fruit.

The Motley Fool • Jul 10, 2026

Is This Biotech Stock a Buy Near Its 52-Week High?

Vertex Pharmaceuticals is making clinical and regulatory progress with some promising candidates. The company's most important business is still performing well.

The Motley Fool • Jul 10, 2026

Why Crinetics Stock Soared 99% This Week

Crinetics Pharmaceuticals (NASDAQ:CRNX | CRNX Price Prediction) shares have climbed 99% just this week, from $42.03 at Monday's close, to $83.54 earlier today.

24/7 Wall Street • Jul 9, 2026

Jim Cramer Says Biotech is The Hottest Group in The Market Right Now

CNBC's Jim Cramer pushed viewers away from the usual semiconductor and hyperscaler chatter.

24/7 Wall Street • Jul 9, 2026

Nvidia, Vertex Pharmaceuticals And More On CNBC's ‘Final Trades'

On CNBC's “Halftime Report Final Trades,” Bryn Talkington, managing partner of Requisite Capital Management, named Roundhill Memory ETF (NASDAQ:DRAM) as her final trade.

Benzinga • Jul 9, 2026